Associated tags: Hook effect, Trastuzumab, NMPA, Rituximab, Name, Patient, Cancer, MSI, Adalimumab, GMP, Bevacizumab, ESCC, SCLC, Pharmaceutical industry, Research, Lung cancer, Mab
Locations: CHINA, MAB, UNITED KINGDOM, EC, EUROPEAN UNION, LATIN AMERICA, FRANCE, SPAIN, FINLAND, ARGENTINA, SAUDI ARABIA, EU, AUSTRALIA, NORTH AMERICA, ASIA, GERMANY, EUROPE, THAILAND, OCEANIA, SWITZERLAND, UNITED STATES, ASIA PACIFIC, NEW JERSEY, CANADA, BRAZIL, INDONESIA
Retrieved on:
Tuesday, February 18, 2020
During this all-day SAB meeting, the topics focused on the presentation and discussion of Henlius' most advanced research projects including scientific justification, competitive landscape, data update and future plans.
Key Points:
- During this all-day SAB meeting, the topics focused on the presentation and discussion of Henlius' most advanced research projects including scientific justification, competitive landscape, data update and future plans.
- Dr. Scott Liu, Henlius co-founder and Chief Executive Officer, started the meeting with an introduction of Henlius, focusing on Henlius' vision and mission of affordable innovation, company history and strategy, commercialization plan and commitment to Research.
- Dr. Alvin Luk, Henlius Senior Vice President and Chief Medical Officer, provided an overview on Henlius Clinical strategy and pipeline, especially HLX10 anti-PD1 programs.
- It is decided that the frequency of the SAB meeting shall be increased and the next SAB meeting is scheduled in mid-2020.
Retrieved on:
Wednesday, November 6, 2019
Henlius stood out from hundreds of enterprises over the past two months, during which the committee comprising about 20 expert judges invited from the generics and biosimilars industries engaged in the judging process independently.
Key Points:
- Henlius stood out from hundreds of enterprises over the past two months, during which the committee comprising about 20 expert judges invited from the generics and biosimilars industries engaged in the judging process independently.
- The recognition by "Global Generics & Biosimilars Awards 2019" not only highlights Henlius' impressive performance in the biotech industry, but also recognizes the company's influence in Asia-Pacific, and even in the global biopharmaceutical markets.
- Moreover, it fills the market gap for biosimilars in China and improves the patients' access to high quality biological medicine.
- In addition to one product launched commercially, Henlius has conducted over 30 clinical studies for 14 products and 6 combination therapies worldwide.
Retrieved on:
Wednesday, November 6, 2019
Henlius stood out from hundreds of enterprises over the past two months, during which the committee comprising about 20 expert judges invited from the generics and biosimilars industries engaged in the judging process independently.
Key Points:
- Henlius stood out from hundreds of enterprises over the past two months, during which the committee comprising about 20 expert judges invited from the generics and biosimilars industries engaged in the judging process independently.
- The recognition by "Global Generics & Biosimilars Awards 2019" not only highlights Henlius' impressive performance in the biotech industry, but also recognizes the company's influence in Asia-Pacific, and even in the global biopharmaceutical markets.
- Moreover, it fills the market gap for biosimilars in China and improves the patients' access to high quality biological medicine.
- In addition to one product launched commercially, Henlius has conducted over 30 clinical studies for 14 products and 6 combination therapies worldwide.
Moreover, at the 2019 American Association for Cancer Research (AACR) annual meeting, Ascentage Pharma has already presented results from several preclinical studies that demonstrated APG-2575's potential in combination therapies.
Key Points:
- Moreover, at the 2019 American Association for Cancer Research (AACR) annual meeting, Ascentage Pharma has already presented results from several preclinical studies that demonstrated APG-2575's potential in combination therapies.
- Potentially this combination could also be extended to other B cell malignancies
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, commented: "We are delighted to be entering this collaboration agreement with Henlius.
- The teams from Ascentage Pharma and Henlius will work closely to explore the clinical utility of this combination therapy.
- In future, Henlius and Ascentage Pharma will press forward with the combination therapy, and provide more treatment options for patients in China."
